Project Grant R44CA221491

The National Cancer Institute (NCI) awarded a $1,003,173 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Radiopharmaceutical Imaging And Dosimetry, LLC, a company based in Baltimore, Maryland. The funding supports the development of a prototype web/cloud-based quantitative SPECT reconstruction software system for use in clinical trials and ultimately clinical dosimetry for radiopharmaceutical therapy (RPT). The software aims to enable accurate quantitative imaging...

Grant Award Summary The University of Pennsylvania received a $695,205 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct early-phase clinical trials of 211-astatine-meta-astatobenzylguanidine (211At-MABG) for treating neuroblastoma in children and advanced neuroendocrine cancers in adults. The award period runs from June 1, 2025, through May 31, 2030. The research addresses limitations of existing treatments,...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...

Onc.ai, Inc. received a $1.69M Phase II Small Business Innovation Research (SBIR) award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to further develop and validate a deep learning radiomics biomarker for improved early response assessment in metastatic cancer therapy trials. The company is developing SerialCTRS (Serial CT Response Score), a fully automated deep learning model that analyzes baseline and follow-up computed tomography...

This $255,730 National Science Foundation project grant supports the development of self-assembling molecular brachytherapy for treatment of metastatic cancer. The goal is to enable radiation therapies for metastatic cancer, which accounts for approximately 90% of cancer deaths in the United States each year. The grantee, Oncurie, LLC, seeks to advance a radiotherapy approach that exploits cancer cells themselves as catalysts for therapeutic delivery. Specifically, the company will develop an...

Federal Grant Award Summary Fusion Energy Solutions, Inc. (doing business as Serva Energy) received a $1.99 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on September 18, 2025, to develop Good Manufacturing Practice (GMP)-grade Terbium-161 as a therapeutic radiopharmaceutical for cancer treatment. This direct-to-Phase II Small Business Innovation Research (SBIR) award, scheduled for completion by August 31, 2027, addresses...

Federal Project Grant Summary The National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded $683,885 to The University of Texas Southwestern Medical Center on May 1, 2026, for a five-year project concluding April 30, 2031. The award funds the development of the first clinical prototype for proton minibeam radiation therapy (PMBRT), an advanced spatially fractionated radiation therapy modality designed to improve upon conventional radiation therapy by delivering a highly...

Federal Project Grant Award Summary The University of Texas at Austin received a $618,695 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop an adaptive and reconfigurable robot-assisted Single Photon Emission Computed Tomography (SPECT) imaging system. Over the three-year performance period (April 20, 2026 through March 31,...

Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $641,419 Project Grant on May 7, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support clinical translation and evaluation of a novel positron emission tomography (PET) theranostic agent for metastatic castrate-resistant prostate cancer (MCRPC). The primary deliverable is the first-in-man clinical imaging study of [77Br]Br-WC-DZ, a bromine-77 ligand targeting...

Radiasoft LLC was awarded a $204,297 Project Grant from the Department of Energy Office of Science under the Office of Science Financial Assistance Program (CFDA 81.049) to support work titled "RAPID ELECTRON BEAM MODELING AT UNPRECEDENTED PHASE SPACE DENSITIES" from June 27, 2022 through June 26, 2023. The grant funding will allow Radiasoft LLC to deliver products and services focused on modeling electron beam dynamics at extremely high phase space densities, a priority research...